erlotinib hydrochloride has been researched along with vardenafil dihydrochloride in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (vardenafil dihydrochloride) | Trials (vardenafil dihydrochloride) | Recent Studies (post-2010) (vardenafil dihydrochloride) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 780 | 151 | 289 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashby, CR; Chen, ZS; Kathawala, RJ; Wang, YJ | 1 |
1 review(s) available for erlotinib hydrochloride and vardenafil dihydrochloride
| Article | Year |
|---|---|
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
Topics: Antineoplastic Agents; Benzamides; Benzylisoquinolines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Imidazoles; Lapatinib; Multidrug Resistance-Associated Proteins; Piperazines; Purines; Pyrimidines; Quinazolines; Sildenafil Citrate; Sulfonamides; Sulfones; Taxoids; Triazines; Vardenafil Dihydrochloride | 2014 |